Traditional cardiovascular trials require tracking thousands of patients across years to measure rare clinical events like heart attacks. Reversing plaque creates a sharper statistical distinction versus control groups than simply slowing growth. This differential may allow drug developers to shorten observation timelines and reduce patient cohort sizes.
When synthetic therapies exist as isomeric mixtures lacking single distinct chromatographic peaks, standard small-molecule CMC playbooks fail. Matthew O'Connor notes that regulatory agencies focus heavily on safety and manufacturing consistency, treating isomeric characterization challenges more like a complex biologic than a conventional small molecule.
Synthetic dimer drugs require multiple synthetic steps and liquid formulations that prevent ultra-cheap generic margins. Even so, Matthew O'Connor emphasizes that production costs remain lower than therapeutic antibodies, enabling massive batch manufacturing without challenging or exceeding standard bioprocessing equipment capacities.
Systemically suppressing specific cell-signaling pathways often produces debilitating off-target toxicity throughout the body. Conversely, therapies designed to eliminate universally toxic metabolites like oxidized cholesterol address root causes of cellular aging, meaning systemic off-target distribution can produce positive therapeutic effects across multiple organs instead of adverse reactions.
Cardiovascular assessment has rapidly transitioned away from invasive catheter angiograms toward non-invasive CT and MRI scans. Combining full-body imaging with artificial intelligence detects microscopic vascular changes before physical symptoms appear, creating a pathway to treat and reverse arterial plaque well before emergency hospitalizations occur.
